Related Experiment Video

Updated: Jul 6, 2026

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response
12:50

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response

Published on: September 15, 2017

[Proinflammatory cytokines in cardiovascular diseases as potential therapeutic target]

Agata Bielecka-Dabrowa1, Magdalena Wierzbicka, Jan H Goch

  • 1Z Kliniki Kardiologii I Katedry Kardiologil i Kardiochirurgii Uniwersytctu Medycznego w Łodzi. agatbiel7@poczta.onet.pl

Wiadomosci Lekarskie (Warsaw, Poland : 1960)
|March 21, 2008
PubMed

Insights

Inflammation, driven by proinflammatory cytokines, contributes to heart failure. While anti-TNF therapies show limited success, immune modulation remains a key area for new cardiovascular disease treatments.

Area of Science:

  • Cardiology
  • Immunology
  • Biomedical Science

Context:

  • Inflammation is increasingly recognized as a key factor in congestive heart failure (CHF) pathogenesis.
  • Proinflammatory cytokines mediate immune responses and are linked to endothelial dysfunction in cardiovascular diseases.
  • Elevated cytokine levels in tissue and circulation suggest immune activation contributes to cardiac and peripheral CHF symptoms.

Purpose:

  • To review the diagnostic and prognostic value of proinflammatory cytokine activation in cardiovascular diseases.
  • To elucidate the role of cytokines in the pathogenesis of heart failure and related conditions.
  • To explore novel therapeutic strategies targeting immune modulation for cardiovascular diseases.

Summary:

  • Evidence links inflammation and proinflammatory cytokines to heart failure progression, affecting contractility, hypertrophy, apoptosis, and remodeling.
  • Current cardiovascular drugs have minimal impact on the cytokine network.
  • Randomized trials of anti-TNF therapy have yielded inconclusive results, yet immune modulation research continues.

Impact:

  • Highlights the diagnostic and prognostic utility of assessing cytokine activation in cardiovascular patients.
  • Underscores the pathogenic role of immune responses in heart failure development and progression.
  • Identifies potential new therapeutic avenues focusing on immune modulation for treating cardiovascular diseases.

Related Concept Videos

Psychoneuroimmunology: Cardiovascular Disease01:27

Psychoneuroimmunology: Cardiovascular Disease

Psychoneuroimmunology (PNI) is a multidisciplinary field that examines how psychological factors, particularly stress, interact with the immune system and impact physical health. Research in PNI has shown that chronic or traumatic stress can disrupt both the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. These disruptions contribute to serious health conditions, including cardiovascular diseases.
A key area of focus in PNI is the relationship between stress and coronary...
Inflammatory Response01:28

Inflammatory Response

An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inflammatory Response I: Vascular and Cellular01:30

Inflammatory Response I: Vascular and Cellular

The inflammatory response is the body's defense against infection, injury, or irritation from bacteria, trauma, toxins, or heat. Inflammation helps locate and destroy pathogens and remove damaged tissue elements to heal the body. During this initial phase, fluid, blood products, and nutrients migrate to the injured area, resulting in redness, heat, swelling, ache, and loss of function. Moreover, signs of systemic inflammation include fever, increased WBC count, malaise, anorexia, nausea,...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...